Clinical trials: Neoplasms Recurrence
MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
This phase I trial studies the side effects and best dose of alisertib and romidepsin in treating patients with B-cell or T-cell lymphomas that have returned after a period of improvement (relapsed) or have not responded to…
- Conditions
- MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01897012
- Testing
- Alisertib, Laboratory Biomarker Analysis, Romidepsin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer (Post Prostatectomy)
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
- Trial name
- NCT06617481
- Testing
- 18F-rhPSMA-7.3 (Posluma)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains…
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT05554328
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 295 sites in United States, Puerto Rico
- Volunteers
- 165 people
- Sponsor
- National Cancer Institute (NCI)
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm
- Trial name
- NCT02359565
- Testing
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
This early phase I trial tests brain concentration level and safety of defactinib or VS-6766 for the treatment of patients with glioblastoma.
- Trial name
- NCT05798507
- Testing
- Avutometinib, Biospecimen Collection, Defactinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Non-Hodgkins Lymphoma
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
- Trial name
- NCT00054834
- Testing
- hLL2 (epratuzumab)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gilead Sciences
Uterine Cervical Cancer
Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
Using albumin-bound paclitaxel and nedaplatin in the advanced or recurrent metastasis cervical cancer, to evaluate the efficacy and toxic reaction.
- Trial name
- CSAPPPCC (NCT01667211)
- Testing
- albumin-bound paclitaxel plus nedaplatin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT02099864
- Testing
- Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004001
- Testing
- docetaxel, estramustine, mitoxantrone
- Where
- 16 sites in United States
- Volunteers
- 770 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Malignant Tumor of Peritoneum, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT01494012
- Testing
- stereotactic body radiation therapy, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Ovarian Clear Cell Carcinoma, Gynecologic Cancer
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer.
- Trial name
- NCT05296512
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Elizabeth K. Lee MD
Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Ph1 Positive CML
- Trial name
- NCT01159028
- Testing
- BP1001, BP1001 in combination with LDAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bio-Path Holdings, Inc.
Glioblastoma, Adult, EGFR Amplification
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.
- Trial name
- NCT03618667
- Testing
- GC1118
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Samsung Medical Center
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment…
- Trial name
- NCT03629171
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine, Venetoclax
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer
- Trial name
- NCT00855764
- Testing
- Paclitaxel
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00024232
- Testing
- monoclonal antibody huJ591
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Beyond Milan Criteria
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
Surgical resection is the primary curative treatment for patients with hepatocellular carcinoma (HCC), with a 5-year overall survival rate of 60-80% post-surgery.
- Trial name
- NCT06467799
- Testing
- Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Triple Negative Breast Cancer
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
- Trial name
- NCT06908928
- Testing
- bulumtatug fuvedotin
- Where
- 7 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00368992
- Testing
- cetuximab, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastatic Cancer
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Metastatic Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005944
- Testing
- chemotherapy, fluorouracil, leucovorin calcium
- Where
- 18 sites in Belgium, France
- Sponsor
- UNICANCER
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.